Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) has successfully completed two Phase III clinical trials (SYMPHONY-1 and SYMPHONY-2) for HTD1801 in patients with Type 2 Diabetes Mellitus (T2DM), demonstrating positive efficacy and safety results over a 52-week period [1][2] Group 1: Clinical Trial Results - The 52-week data from the two Phase III clinical studies confirm the durability of HTD1801's efficacy, highlighting its long-term comprehensive clinical benefits for T2DM patients [1] - The proportion of patients achieving HbA1c targets (HbA1c < 7.0%) remained stable at week 52 during the double-blind period [1] - HTD1801 showed sustained efficacy in lipid reduction, with significant decreases in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) [1] Group 2: Inflammatory Markers and Cardiovascular Benefits - Long-term treatment with HTD1801 also led to sustained reductions in inflammatory markers closely related to cardiovascular events and clinical outcomes in T2DM patients, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP) [1] Group 3: Safety and Tolerability - HTD1801 demonstrated good safety and tolerability during long-term treatment, consistent with double-blind results, indicating that extending the treatment period does not increase the types or severity of adverse events for patients [2]

Core Insights - Junsheng Tai Pharmaceutical-B (02511) has successfully completed two Phase III clinical trials (SYMPHONY-1 and SYMPHONY-2) for HTD1801 in patients with Type 2 Diabetes Mellitus (T2DM), demonstrating positive efficacy and safety results over a 52-week period [1][2] Group 1: Clinical Trial Results - The 52-week data from the two Phase III clinical studies confirm the durability of HTD1801's efficacy, highlighting its long-term comprehensive clinical benefits for T2DM patients [1] - The proportion of patients achieving HbA1c <7.0% remained stable at week 52 during the double-blind period [1] - HTD1801 showed sustained efficacy in lipid reduction, with significant decreases in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) [1] Group 2: Inflammatory Markers and Cardiovascular Benefits - Long-term treatment with HTD1801 also led to a continuous reduction in inflammatory markers closely related to cardiovascular events and clinical outcomes in T2DM patients, including gamma-glutamyl transferase (GGT) and high-sensitivity C-reactive protein (hs-CRP) [1] Group 3: Safety and Tolerability - HTD1801 demonstrated good safety and tolerability during long-term treatment, consistent with double-blind results, indicating that extending the treatment period does not increase the types or severity of adverse events for patients [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 HighTide Therapeutics, Inc. （於開曼群島註冊成立的有限公司） （股份代號：2511） 全球首創抗炎代謝調節劑HTD1801完成2型糖尿病III期臨床研究 展現持續52周的綜合獲益與安全性優勢 本公告由君聖泰醫藥（「本公司」，連同其附屬公司統稱為「本集團」）自願發佈，以 告知本公司股東及潛在投資者有關本集團的最新業務發展。 本公司董事會（「董事會」）宣佈，HTD1801在2型糖尿病(T2DM)患者中開展的兩項 III期臨床試驗（SYMPHONY-1和SYMPHONY-2）已順利完成，52周研究（含開放 標籤延長期(OLE)）取得積極的療效與安全性結果。 52周研究結果進一步驗證，HTD1801可調節代謝、抑制炎症並改善腎功能，有潛 力作為差異化療法從多維度改善2型糖尿病的疾病進程 兩項III期臨床研究的52周數據充分驗證了HTD1801療效的持久性，並進一步凸顯 其為T2DM患 ...

Core Insights - The recent data from the lottery indicates a trend in the number distribution and expected outcomes for upcoming draws [1][2][3] Front Area Analysis - In the last 10 draws, the 0-route numbers have appeared 16 times, with 3 numbers drawn in the last draw, indicating a hot trend. A decrease in the number of drawn numbers is expected, focusing on the number 18 [1] - The 1-route numbers have also appeared 16 times in the last 10 draws, with only 1 number drawn last time, suggesting a cold trend. An increase in drawn numbers is anticipated, focusing on numbers 07, 10, and 34 [2] - The 2-route numbers have been drawn 18 times in the last 10 draws, with 1 number drawn last time, indicating a cold trend. A decrease in drawn numbers is expected, focusing on the number 35 [2] Odd-Even Analysis - The last draw had 3 odd numbers and 2 even numbers, resulting in an odd-even ratio of 3:2. Over the last 10 draws, the overall odd-even ratio is 23:27, suggesting that even numbers have appeared more frequently. An expectation for more even numbers is noted, with a recommended odd-even ratio of 2:3 for the next draw [3] Back Area Analysis - The last draw's back area numbers were 09 and 12, with a sum of 21, which has increased from the previous draw. A decrease in the sum is expected for the next draw, with a focus on numbers 03 and 10, and a target sum of 13 [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君圣泰医药（於開曼群島註冊成立的有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02511 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | 0.0001 | USD | | 100,000 | 本月底法定/註冊股本總額： USD ...

中期報告 2025 目錄 | 公司資料 | 2 | | --- | --- | | 管理層討論及分析 | 4 | | 其他資料 | 23 | | 獨立審閱報告 | 43 | | 簡明綜合損益表 | 45 | | 簡明綜合全面收益表 | 46 | | 簡明綜合財務狀況表 | 47 | | 簡明綜合權益變動表 | 49 | | 簡明綜合現金流量表 | 50 | | 中期簡明財務報表附註 | 52 | | 釋義 | 64 | 公司資料 公司資料 執行董事 劉利平博士 （本公司董事會主席兼行政總裁） 于萌女士 非執行董事 朱迅博士 馬立雄先生 （董事會副主席） 江峰先生 獨立非執行董事 譚擘先生 李靖博士 孔德偉先生 審核委員會 譚擘先生 （主席） 李靖博士 孔德偉先生 薪酬委員會 李靖博士 （主席） 劉利平博士 譚擘先生 提名委員會 劉利平博士 （主席） 李靖博士 孔德偉先生 聯席公司秘書 高麗萍女士 朱璧敏女士 授權代表 劉利平博士 朱璧敏女士 中國總辦事處及主要營業地點 中國廣東省 深圳市福田區 福保街道福保社區 深港科技創新合作區 D棟第九層至十層 香港主要營業地點 香港 灣仔 皇后大道東248號 大新金融中 ...

Group 1 - The report details the results of food safety inspections conducted by the Binzhou Market Supervision Administration, highlighting various food products that passed the tests [2][3][4] - A total of 50 food products were sampled, including various types of mooncakes, with specific details on the manufacturers, product types, and sampling dates provided [2][3] - The inspected products include traditional mooncake varieties such as Su-style mooncakes with different fillings, indicating a focus on seasonal products ahead of the Mid-Autumn Festival [2][3] Group 2 - The report lists manufacturers such as Shijiazhuang Yinnainai Food Co., Ltd. and Shijiazhuang Jiajia Food Trade Co., Ltd., showcasing the regional production of mooncakes [2][3] - Specific product details include packaging sizes, such as 400 grams and 430 grams for various mooncake types, indicating standardization in product offerings [2][3] - The inspection results reflect the regulatory efforts to ensure food safety and quality in the local market, which is crucial for consumer trust [2][3]

Core Viewpoint - Junsheng Tai Pharmaceutical-B (2511.HK) continues its upward trend, reaching a new high since mid-June 2024, with a significant increase in market value and a notable reduction in losses compared to the previous year [1] Financial Performance - In the first half of 2025, the company reported a loss of 113.9 million HKD, a substantial improvement from a loss of 210.9 million HKD in the same period of 2024 [1] Product Pipeline - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system, currently under development for various CKM-related diseases [1] - HTD1801 is being developed for the treatment of Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1] - In addition to HTD1801, the company has a strong pipeline of innovative drug candidates, including HTD4010, HTF1037, HTF1057, HTD1804, HTD1805, and HTD2802, targeting a total of ten potential indications [1]

| 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02511 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | 100,000 | 本月底法定/註冊股本總額： USD 100,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君圣泰医药（於開曼群島註冊成立的有限公司） 呈交日期: 2025年9月1日 I. 法定/ ...

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million, following the release of its interim results for the six months ending June 30, 2025 [1] Financial Performance - Other income for the company was RMB 10.542 million, representing a year-on-year decrease of 69.96% [1] - The loss attributable to shareholders was RMB 120 million, which narrowed by 42.96% year-on-year [1] - Basic loss per share was RMB 0.27 [1] Product Development - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is currently under global development for the treatment of CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]